cdp.cancer.gov
Open in
urlscan Pro
2607:f220:41d:21c1::812b:fe66
Public Scan
Submitted URL: http://www.cancerdiagnosis.nci.nih.gov/
Effective URL: https://cdp.cancer.gov/
Submission: On December 04 via api from US — Scanned from AU
Effective URL: https://cdp.cancer.gov/
Submission: On December 04 via api from US — Scanned from AU
Form analysis
1 forms found in the DOMName: SearchForm — GET /search/search.asp
<form action="/search/search.asp" method="get" enctype="application/x-www-form-urlencoded" name="SearchForm" id="SearchForm" onsubmit="return validate_search();">
<label id="searchLabel" for="zoom_query">Search this site</label>
<input type="text" name="zoom_query" id="zoom_query" maxlength="255" class="search" value="Search this site">
<input class="searchButton" id="mobileSearchButton" type="image" src="/images/redesign/mb_search.png" name="Action" alt="Search">
</form>
Text Content
Skip to Content Home | Sitemap | Contact CDP Search this site * Home * About CDP * Mission Statement and Branches * Staff Directory * Office of the Associate Director (OAD) * Biorepositories and Biospecimen Research Branch (BBRB) * Diagnostic Biomarkers and Technology Branch (DBTB) * Diagnostics Evaluation Branch (DEB) * Pathology Investigation and Resources Branch (PIRB) * Scientific Programs * Precision Medicine Trials * MoCha Lab * Exceptional Responders * CIMAC-CIDC * Strategic Partnering to Evaluate Cancer Signatures (SPECS) * Overview * SPECS Projects * TAILORx * Funding Opportunities * Current Funding Opportunities * Complete List of Cancer Diagnosis Program Initiatives * P01 Program Development Guidance * Additional Funding Opportunities and Useful Tools * Resources * Templates for Clinical Assay Development * Assay Harmonization Resources * Technology Development Resources * Diagnostics Research and Development Resources * Human Specimen Resources * Ethical, Legal and Social Implications of Biobanking in Cancer Research * News and Publications * News * Publications * Recommendations * Funding Opportunities * GTEx Biobank * NCTN Navigator * Clinical Trial Applications WELCOME TO THE CANCER DIAGNOSIS PROGRAM! The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment. For more information about the Cancer Diagnosis Program and its Branches, please click here. NEWS AND ANNOUNCEMENTS 10/2024 Registration is now open for the Transformative Microsystem Technologies for Cancer Diagnostics, Monitoring Treatment Response, and Management Workshop, taking place virtually on February 5-6, 2025. View the agenda and register for the workshop on the event website here. 02/2024 Summary and recordings from the March 2024 NCI Workshop on Digital Pathology Imaging (DPI) in Cancer Clinical Trials and Research are now available here. 07/2023 Summary and recordings from the September 2023 NCI Workshop on ctDNA in Cancer Treatment and Clinical Care are now available here. 01/2023 Guidance for investigators interested in P01 Funding for DCTD research areas is now available here. 06/2022 Visit this page to see the schedule of CDP and other DCTD programs presentations at 2022 ASCO. 04/2022 Click here to see a list of presentations by CDP and other DCTD programs at 2022 AACR. 03/2022 CDP’s Dr. Magdalena Thurin participated in ASCO/CAP Immune Checkpoint Inhibitor (ICI) Predictive Factor Virtual Summit in September 2021; slides and recordings are now available here. 11/2021 In September, NCI hosted the FDA/NIH Next Generation Sequencing and Radiomics Workshop: Resource Requirements for Acceleration of Clinical Applications Including Artificial Intelligence. 10/2021 CDP's Dr. Brian Sorg is involved in a cross-agency collaboration with NASA, FDA, NIH, and HHS's BARDA that could lead to unprecedented advancements personalized medicine by extending the life of tissue chips. 09/2021 Dr. Lyndsay Harris, Associate Director of the CDP, commemorates the 50th anniversary of the National Cancer Act with a Staff Highlight in the DCTD newsletter on the evolution of cancer biomarkers, diagnostics, and where research is headed. QUICK LINKS P01 Program Development Guidance NCI COVID-19 Research Initiatives The NCI Grants Process Templates for Clinical Assay Development Biorepositories and Biospecimen Research Branch “Omics” Checklist — Criteria For Use of Omics-based Predictors in Clinical Trials Ethical, Legal and Social Implications of Biobanking in Cancer Research NCI-MATCH/EAY131 Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) STAY CONNECTED Sign up for Email Updates Follow us on Twitter Contact Us * CDP Home * Contact CDP * Site Map * Accessibility * Disclaimer * FOIA * Privacy & Security * HHS Vulnerability Disclosure * U.S. Department of Health and Human Services * National Institutes of Health * National Cancer Institute * USA.gov NIH… Turning Discovery Into Health®